The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,026.00
Bid: 11,054.00
Ask: 12,100.00
Change: 0.00 (0.00%)
Spread: 1,046.00 (9.463%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-AstraZeneca suffers setback as drug fails in eye cancer

Wed, 22nd Jul 2015 07:26

* Selumetinib fails in Phase III trial for uveal melanoma

* Drug continues to be tested in lung, other cancers

* 2020 consensus sales forecast for selumetinib $305 mln (Adds sales forecast, analyst comment, disease details)

By Ben Hirschler

LONDON, July 22 (Reuters) - AstraZeneca's muchanticipated cancer drug pipeline suffered a modest blow onWednesday when the experimental drug selumetinib failed to meetits goal in a late-stage trial for a rare cancer of the eye.

The drugmaker said the disappointing result in uvealmelanoma would not affect other studies using the drug.Selumetinib is being investigated primarily as a treatment foradvanced non-small cell lung cancer.

Selumetinib belongs to a class of cancer drugs known as MEKinhibitors, which includes Novartis's approved productMekinist and the experimental compound cobimetinib from Roche and Exelixis.

Current consensus analyst forecasts for selumetinib, whichis designed for use alongside chemotherapy, point to relativelyminor sales of $305 million in 2020, according to ThomsonReuters Cortellis.

Berenberg analyst Alistair Campbell said the failure of thePhase III trial, known as SUMIT, was a surprise after verypromising Phase II data.

"However, selumetinib is not one of the big three oncologydrugs (AZD9291, Lynparza and MEDI4736) that will lead theturnaround of Astra's fortunes in oncology," he wrote in a note.

Shares in the drugmaker fell 0.7 percent in early trading.

Uveal melanoma is a disease in which cancer cells grow inthe tissues of the eye. Although rare, it is the most commonprimary intraocular malignancy in adults and accounts for 5percent of all melanomas.

The bigger commercial opportunity for AstraZeneca would bein using the drug in lung cancer. Selumetinib is also beingstudied in thyroid cancer and neurofibromatosis, a condition inwhich tumours grow along the nerves.

"Selumetinib is supported by a strong development programmewith different scientific rationale in multiple tumour types asboth monotherapy and in alternative combinations," saidAstraZeneca's oncology development head Antoine Yver.

"The findings from SUMIT have no impact on the other studiesand we look forward to presenting the data in due course."

Oncology is a priority area for AstraZeneca and the groupaims to launch six new cancer medicines by 2020.

(Reporting by Ben Hirschler; Editing by Louise Heavens andKeith Weir; by Louise Heavens)

More News
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 09:48

LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.